Pfizer's Chantix Might Revolutionize the Smoking Cessation and Addiction Treatments Market By 2010
July 20, 2007
Conceiving the report of Report Buyer, an online podium for comprehensive business information on major industry sectors, Pfizer's Chantix or varenicline could transform the whole addiction treatments market by 2010.
According to the claim of a novel report titled “Smoking Cessation and Addiction Treatments - A World Market Analysis”, Chantix may impel the global sales churned out of smoking cessation and other addition treatments to above $2.3 billion in 2010, in conjunction with the fact that addiction treatments are blessed with greater reimbursements levels.
At present, nearly 1.4 billion people are addicted to smoking world wide. A substantial total of smokers now use nicotine and thus, it is counted among the highly abused substances across the globe.
Since smoking results a number of heart and lung diseases, campaigns outlined to cease smoking now are on the top of priority list of global health agencies and governments too. This eventually led to enhanced awareness about the drawbacks of nicotine use as well as accessibility of effectual smoking cessation products. This simply implies that any new smoking cessation medicine will experience a robust growth if make foray in to the market.
Currently, GlaxoSmithKline’s, Shering Plough / Reckitt Benckiser uphold the maximum share of the smoking cessation and addiction treatments market with Zyban, Suboxone/Subetex respectively. Analysts expect that Pfizer’s influx in to the smoking cessation segment with Chantix would boost up the global sales’ scale.
Authors of the report think that Pfizer’s Chantix, also known as Champix in Europe, might surpass GlaxoSmithKline and all other contenders in smoking cessation’s segment with its superior efficacy during clinical trial phase.
The report encloses world incidence data for nicotine addiction, alcohol abuse and drug addiction. Not only this, it comprises the list of currently available products in addition to a review of products in the pipeline. The study further highlights the key trends impelling pharmaceutical treatments for smoking cessation, drug and alcohol addiction. |
